Over the past few years, GLP-1 receptor agonists have moved from a niche diabetes treatment to one of the most in-demand drug classes globally. Medicines such as semaglutide and tirzepatide are now widely used not only for type 2 diabetes but increasingly for obesity and metabolic disease. Demand Is Outpacing Supply Global demand for GLP-1 therapies has surged due to increased global trial activity involving GLP-1 comparators, expanding indications and it’s increasing availab

Cold-chain logistics play a pivotal role in pharmaceutical supply, ensuring patient safety and trial continuity. This is especially true in the oncology sector, where most therapies are temperature-sensitive and in high demand, amplifying the need for robust cold-chain infrastructure. Cold-chain logistics refers to the temperature-controlled transport and storage of pharmaceutical products. For biologics, cell and gene therapies and many oncology medications, maintaining a na

The movement of investigational medicinal products (IMPs) and comparators across borders can be a complex undertaking with customs regulations, import/export requirements, and VAT considerations. CSI supports its clients by removing this complexity and ensuring that clinical supplies move efficiently, compliantly and without delay. Global expertise, local execution Our team has extensive experience navigating country-specific regulations, documentation requirements, and impor

Understanding the Impact of Tariffs on Clinical Trials Recent headlines about proposed US tariffs on European countries highlight the volatility of the global trade environment. As reported this week in Fierce Pharma , potential new duties on several European nations raise questions about the future of US–EU trade relations. This uncertainty can significantly impact the pharmaceutical industry. For sponsors running global clinical trials, this kind of uncertainty translates i

Client: Mid-size biotech conducting multiple clinical trials Challenge: The client required a large quantity of Humira (adalimumab) for several upcoming studies. High costs and limited availability were putting pressure on study budgets and timelines. Solution: CSI leveraged its industry insight and direct relationships with the manufacturer to provide access to a high-quality adalimumab biosimilar. This saved the client a staggering 50% on price. By carefully coordinating so

A Message of Joy and Gratitude From all of us at Clinical Services International (CSI), we wish you a joyful and peaceful holiday season! As we reflect on the past year, we are filled with gratitude for the incredible partnerships, teamwork, and milestones we have achieved together. This season is a time for celebration and appreciation. Special Christmas Video To commemorate this special time, we have created a heartfelt Christmas video. This video highlights the remarkable

On the 12th day of Christmas CSI gave to me… Twelve reasons sponsors trust CSI, all year long! On the 1st day of Christmas CSI gave to me… Direct Manufacturer Access! Receive faster timelines and documentation thanks to CSI’s direct accounts with global pharma leaders. Reach out to CSI for a sourcing consultation, no matter how big or small your request. On the 2nd day of Christmas CSI gave to me… Unmatched sustainability; with an EcoVadis Platinum rating, putting us in th

As we prepare for Q1 2026, sponsors and CROs face a shifting global landscape for clinical trial comparator sourcing that focuses on sustainability, diversity and fair pricing. With our EcoVadis Platinum certification, women-owned business status and full scientific team in place, CSI is well placed to support our partner’s supply chains. 1. Supply-chain volatility is real Clinical supplies are increasingly challenged by geo-political pressures, export controls, and manufactu

By Clinical Services International As a proud Women-Owned Business , Clinical Services International (CSI) is committed to transforming the global clinical supply landscape while championing gender equity and social responsibility. Founded on the principles of scientific excellence, ethical sourcing and diversity, CSI stands at the forefront of pharmaceutical procurement and supply solutions for clinical trials worldwide. Women-owned businesses are vital to the global econo

Client Overview A global biopharmaceutical company approached CSI to support a Phase III oncology study requiring Opdivo (nivolumab) as a comparator. The study spanned 4 countries across North America, Europe and Asia-Pacific, with a target enrolment of over 500 patients. The client’s main objective was to ensure timely delivery of branded Opdivo for multiple trial sites while maintaining transparent, full chain of custody and documentation. Challenge There were several key

At CSI, we’ve built our reputation on being a trusted partner in advancing global health. Among our proudest achievements is our role in...

When it comes to sourcing medicines for Acute Myeloid Leukemia (AML), a supply partner with experience is imperative. At CSI, we’ve built...

At CSI, we understand the urgency and precision required in ophthalmology research. Among the most pressing areas is wet age-related macular degeneration (AMD) a leading cause of vision loss worldwide. Clinical studies in this field demand not only specialized medicines, but also a reliable partner who can ensure seamless supply and global reach. With direct access to all major manufacturers, a fully scientific project team, and a proven track record across ophthalmology prog

Strategy Partnerships for Budget Value As we enter Q4, many clinical operations teams face the familiar challenge of budget utilization. In research-driven organizations, unspent funds create pressure to allocate resources quickly. Yet, reactive decisions can compromise study timelines, inflate costs, or affect compliance. The question becomes: how can sponsors and CROs transform year-end budget pressures into a strategic advantage? From Short-Term Spending to Strategic Inves

Rare disease clinical trials present a distinct set of challenges that make sourcing strategies critical to study success. With fewer patients, limited historical data and small global treatment populations, every component of the trial must be executed with precision, especially the sourcing of comparator drugs and ancillary supplies. In rare disease studies patient recruitment is already difficult. Delays due to drug unavailability or supply chain inefficiencies can have a

In the pharmaceutical industry, timelines serve as both operational benchmarks and market signals. When sponsors announce trial starts and milestones, the investment community pays close attention. But what happens when behind-the-scenes issues, such as delays in sourcing a comparator drug, throw those timelines off track? At Clinical Services International (CSI), we have seen firsthand how comparator drug sourcing, though often underestimated, can become a critical path depe

Rapid Supply of Abraxane in Europe Client Request: Urgent Need for Abraxane A global pharmaceutical sponsor was in a tight spot. They needed 450 packs of Abraxane (nab-paclitaxel) for sites across Europe. Unfortunately, their original supplier could not meet the demand within the required timeline. This situation threatened to delay patient enrolment and jeopardise key study milestones. The Challenge: Overcoming Obstacles The project faced several challenges: Short lead time

Your Global Partner in Clinical Trial Supply At Clinical Services International (CSI), we do more than source medicines, we ensure your...

CSI is proud to drive progress and celebrate the power of diversity. Our team is as global as the studies we support. Representing a...

In an industry where both timelines and budgets are under constant pressure, clinical trial sponsors and CROs are often forced to balance the two most critical resources: time and money. At Clinical Services International (CSI), we work with clients around the world navigating this challenge. And whilst cost control is understandably top of mind, it is often time, not price, that defines success. Price Matters… But Isn’t Everything Sponsors and CROs are understandably price-s